References
1. Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO Classification
of Lung Tumors: Impact of Advances Since 2015. J Thorac Oncol .
Mar 2022;17(3):362-387. doi:10.1016/j.jtho.2021.11.003
2. Sun L, Dai J, Chen Y, et al. Pulmonary Sarcomatoid Carcinoma:
Experience From SEER Database and Shanghai Pulmonary Hospital. Ann
Thorac Surg . Aug 2020;110(2):406-413.
doi:10.1016/j.athoracsur.2020.02.071
3. Yendamuri S, Caty L, Pine M, et al. Outcomes of sarcomatoid carcinoma
of the lung: a Surveillance, Epidemiology, and End Results Database
analysis. Surgery . Sep 2012;152(3):397-402.
doi:10.1016/j.surg.2012.05.007
4. Zhu J, Yuan Y, Wan X, et al. Immunotherapy (excluding checkpoint
inhibitors) for stage I to III non-small cell lung cancer treated with
surgery or radiotherapy with curative intent. Cochrane Database
Syst Rev . Dec 6 2021;12:CD011300. doi:10.1002/14651858.CD011300.pub3
5. Vieira T, Girard N, Ung M, et al. Efficacy of first-line chemotherapy
in patients with advanced lung sarcomatoid carcinoma. J Thorac
Oncol . Dec 2013;8(12):1574-7. doi:10.1097/01.JTO.0000437008.00554.90
6. Howlader N, Forjaz G, Mooradian MJ, et al. The Effect of Advances in
Lung-Cancer Treatment on Population Mortality. N Engl J Med . Aug
13 2020;383(7):640-649. doi:10.1056/NEJMoa1916623
7. Bade BC, Dela Cruz CS. Lung Cancer 2020: Epidemiology, Etiology, and
Prevention. Clin Chest Med . Mar 2020;41(1):1-24.
doi:10.1016/j.ccm.2019.10.001
8. Steuer CE, Behera M, Liu Y, et al. Pulmonary Sarcomatoid Carcinoma:
An Analysis of the National Cancer Data Base. Clin Lung Cancer .
May 2017;18(3):286-292. doi:10.1016/j.cllc.2016.11.016
9. Arabiat M, Bhat P, Steff R, Singh K. A 56-Year-Old Woman With
Nonresolving Pneumonia. Chest . Oct 2021;160(4):e369-e370.
doi:10.1016/j.chest.2020.10.097
10. Wang M, Herbst RS, Boshoff C. Toward personalized treatment
approaches for non-small-cell lung cancer. Nat Med . Aug
2021;27(8):1345-1356. doi:10.1038/s41591-021-01450-2
11. Ettinger DS, Wood DE, Aggarwal C, et al. NCCN Guidelines Insights:
Non-Small Cell Lung Cancer, Version 1.2020. J Natl Compr Canc
Netw . Dec 2019;17(12):1464-1472. doi:10.6004/jnccn.2019.0059
12. Miller M, Hanna N. Advances in systemic therapy for non-small cell
lung cancer. BMJ . Nov 9 2021;375:n2363. doi:10.1136/bmj.n2363
13. Socinski MA, Obasaju C, Gandara D, et al. Current and Emergent
Therapy Options for Advanced Squamous Cell Lung Cancer. J Thorac
Oncol . Feb 2018;13(2):165-183. doi:10.1016/j.jtho.2017.11.111
14. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health
Organization Classification of Lung Tumors: Impact of Genetic, Clinical
and Radiologic Advances Since the 2004 Classification. J Thorac
Oncol . Sep 2015;10(9):1243-1260. doi:10.1097/JTO.0000000000000630
15. Turner BM, Cagle PT, Sainz IM, Fukuoka J, Shen SS, Jagirdar J.
Napsin A, a new marker for lung adenocarcinoma, is complementary and
more sensitive and specific than thyroid transcription factor 1 in the
differential diagnosis of primary pulmonary carcinoma: evaluation of
1674 cases by tissue microarray. Arch Pathol Lab Med . Feb
2012;136(2):163-71. doi:10.5858/arpa.2011-0320-OA
16. Pelosi G, Rodriguez J, Viale G, Rosai J. Typical and atypical
pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on
biopsy specimens: a major pitfall in the management of lung cancer
patients. Am J Surg Pathol . Feb 2005;29(2):179-87.
doi:10.1097/01.pas.0000149690.75462.29
17. Yang SR, Schultheis AM, Yu H, Mandelker D, Ladanyi M, Buttner R.
Precision medicine in non-small cell lung cancer: Current applications
and future directions. Semin Cancer Biol . Sep 2022;84:184-198.
doi:10.1016/j.semcancer.2020.07.009
18. Lebow ES, Murciano-Goroff YR, Brannon AR, et al. MSK-ACCESS for
noninvasive somatic mutation profiling of lung cancers utilizing
circulating tumor DNA. Journal of Clinical Oncology .
2020;38(15_suppl):3529-3529. doi:10.1200/JCO.2020.38.15_suppl.3529
19. Lococo F, Torricelli F, Rossi G, et al. Inter-relationship between
PD-L1 expression and clinic-pathological features and driver gene
mutations in pulmonary sarcomatoid carcinomas. Lung Cancer . Nov
2017;113:93-101. doi:10.1016/j.lungcan.2017.09.009
20. Lantuejoul S, Sound-Tsao M, Cooper WA, et al. PD-L1 Testing for Lung
Cancer in 2019: Perspective From the IASLC Pathology Committee. J
Thorac Oncol . Apr 2020;15(4):499-519. doi:10.1016/j.jtho.2019.12.107
21. Sezer A, Kilickap S, Gumus M, et al. Cemiplimab monotherapy for
first-line treatment of advanced non-small-cell lung cancer with PD-L1
of at least 50%: a multicentre, open-label, global, phase 3,
randomised, controlled trial. Lancet . Feb 13
2021;397(10274):592-604. doi:10.1016/S0140-6736(21)00228-2
22. Abdallah HM, Martinez-Meehan D, Lutfi W, et al. Adjuvant
chemotherapy for pulmonary sarcomatoid carcinoma: A retrospective
analysis of the National Cancer Database. J Thorac Cardiovasc
Surg . May 2022;163(5):1669-1681 e3. doi:10.1016/j.jtcvs.2021.01.081
23. Chaft JE, Sima CS, Ginsberg MS, et al. Clinical outcomes with
perioperative chemotherapy in sarcomatoid carcinomas of the lung.J Thorac Oncol . Sep 2012;7(9):1400-5.
doi:10.1097/JTO.0b013e3182614856